Malignant glioma: Who benefits from adjuvant chemotherapy?

Lisa M. DeAngelis, Peter C. Burger, Sylvan B. Green, J. Gregory Cairncross

Research output: Contribution to journalArticlepeer-review

125 Scopus citations

Abstract

We combined two randomized prospective Brain Tumor Study Group data sets to analyze the effects of prognostic factors on survival by treatment group. Adjuvant chemotherapy increased long-term survival regardless of prognostic factors. Pathological review revealed that oligodendrogliomas were overrepresented among long-term survivors independent of therapy. Prognostic factors do not predict benefit from adjuvant nitrosourea in malignant gliomas, and long-term survival with chemotherapy is not explained by oligodendroglial tumors.

Original languageEnglish (US)
Pages (from-to)691-695
Number of pages5
JournalAnnals of neurology
Volume44
Issue number4
DOIs
StatePublished - Oct 1 1998

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Malignant glioma: Who benefits from adjuvant chemotherapy?'. Together they form a unique fingerprint.

Cite this